Anaphylaxis Update: Strategies for Diagnosis, Prevention, and Treatment e-Monograph

Faculty

Eli O. Meltzer, MD
Co-director
Allergy & Asthma Medical Group and Research Center
Clinical Professor of Pediatrics
University of California, San Diego
San Diego, California

 

Sponsored by:

integrity

Supported by an
educational grant from:

mylan logo us 2 color

Minimum System Requirements

Windows XP, Windows 2000, Windows Vista, and Windows 7 Intel Pentium 4, 2.33 + GHz (or equivalent)
Adobe® Flash® Player 10

Mac OS X v10.4 or later
1.8GHz or faster (or equivalent)
Intel Core Duo 1.33GHz or faster (or equivalent)
Adobe® Flash® Player 1

Click here for more information on minimum system requirements.

Privacy Policy

When you participate in an online educational activity sponsored by Integrity CE, you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and...(continued)

Release date: February 7, 2013
Expiration date: February 7, 2014
Estimated time to complete activity: 1.0 hour

Program Overview

With recent estimates suggesting that there has been a rise in allergic reactions, especially in children and adolescents, it has become critically important that healthcare providers are armed with the most up-to-date information on the diagnosis, prevention, and treatment of anaphylaxis. In the United States, an emegency department visit for anaphylaxis from food occurs every 6 minutes and anaphylaxis from food ingestion or insect stings causes 40 to 200 deaths per year.

Despite substantial progress in the field of anaphylaxis, and recently updated practice guidelines, many clinical questions remain.  An improved understanding of recommended management strategies can prevent urgent care or emergency department visits and reduce the morbidity and mortality associated with anaphylaxis. There is a critical need to align practice standards across the healthcare settings, so that prevention and treatment goals are met in the care of patients with anaphylaxis.

This activity will review the essentials of anaphylaxis management to ensure that optimal care is given to patients who are at risk.

    Target Audience

    This activity has been designed to meet the educational needs of emergency medicine physicians, pediatricians, nurse practitioners, physician assistants, and other healthcare providers involved in the care of patients with anaphylaxis.

    Learning Objectives

    Upon completion of this educational activity, participants should be able to:
          • Implement evidence-based strategies to assess and diagnose anaphylaxis
          • Provide patients and caregivers with education on anaphylactic triggers and real-world strategies for the prevention of anaphylaxis
          • Create emergency action plans with patients and caregivers that incorporate instructions for self-management in an emergency
          • Develop treatment strategies that utilize injectable epinephrine for the treatment of an anaphylactic episode

              Accreditation Statement

              Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

              Credit Designation

              Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

              Disclosure of Conflicts of Interest

              Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of these activities to disclose any real or apparent conflicts of interest they may have as related to the content of these activities. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

              The faculty/planners reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

              Eli O. Meltzer, MD
              Advisory board/Consultant: Adelphi Eden, Alcon, Amgen, Boehringer Ingelheim, Dey, Greer, ISTA Pharmaceuticals, Johnson & Johnson, Kalypsys, Meda, Merck, National Jewish Health, ONO Pharmaceutical, Sandoz, Schering-Plough, Sunovion, Stallergenes, Teva Pharmaceuticals
              Grants/Research support: Alcon, Alexza, Amgen, Astellas, Boehringer Ingelheim, Clinical Resource Network, Forest, GlaxoSmithKline, Johnson & Johnson, MAP, Meda, MedImmune, Merck, Novartis, Sunovion, Teva Pharmaceuticals
              Speaker: Alcon, GlaxoSmithKline, Merck, Nycomed, sanofi-aventis, Schering-Plough, Sunovion

              Sean Gregory, PhD
              Hereby state that he or his spouses/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity or any amount during the last 12 months.

              Directions to the Learner

              There are no fees for participating and receiving CME credit for this activity. During the period of February 7, 2013, through February 7, 2014, participants must:

              • Read the learning objectives and faculty disclosure
              • Complete the pretest
              • Study the educational activity
              • Complete the posttest and evaluation form

              A statement of credit will be issued only upon receipt of a completed posttest with a score of 70% or better and a completed evaluation form. Your statement of credit will be e-mailed to you within 4 weeks.

              Media

              Internet

              Disclosure of Unlabeled Use

              These educational activities may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Mylan Specialty do not recommend the use of any agent outside of the labeled indications.

              The opinions expressed in these educational activities are those of the faculty and do not necessarily represent the views of Integrity Continuing Education, Inc. and Mylan Specialty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

              Disclaimer

              Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in these activities is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

               

              Begin e-monograph pretest

              mono pre

              For questions about the accreditation of this program, please contact Integrity Continuing Education, Inc. at (888) 255-1009 or This email address is being protected from spambots. You need JavaScript enabled to view it. .